KRAS and cancer: These findings highlight the complete inhibition of the MAPK pathway and the subsequent suppression of cancer cell growth and proliferation by SJ-C1044 in colorectal cancer cells harboring mutant KRAS, distinguishing it from Type IIb inhibitors that may exhibit reduced efficacy due to paradoxical activation.